Impaired hepatic lipid metabolism and biomarkers in fatty liver disease

Francisca S. Teixeira, Lígia L. Pimentel*, Manuela E. Pintado, Luís M. Rodríguez-Alcalá*

*Autor correspondente para este trabalho

Resultado de pesquisarevisão de pares

2 Citações (Scopus)


The liver plays a crucial role in lipid metabolism and metabolic homeostasis. Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease worldwide and currently has no specific treatments. Lifestyle modifications such as weight loss, exercise, and dietary changes are recommended to reduce the risk factors associated with the disease. Oxidized cholesterol products, some phospholipids and diacylglycerols can activate inflammatory pathways and contribute to the progression to Non-Alcoholic Steatohepatitis. Monitoring the whole plasma and liver lipidome may provide insights into the onset, development, and prevention of inflammatory-related diseases. As Lipid Droplets (LDs) represent augmented lipid reservoirs in NAFLD, new developments are being made on different therapies focused on LD associated proteins modulation (seipin, PLIN-2), as well as LD lipophagy mechanisms. The information covered in this publication provides an overview of the available research on lipid biomarkers linked to NAFLD and can be used to guide the development of future pharmacological therapies.
Idioma originalEnglish
Páginas (de-até)69-74
Número de páginas6
Estado da publicaçãoPublicado - dez. 2023

Impressão digital

Mergulhe nos tópicos de investigação de “Impaired hepatic lipid metabolism and biomarkers in fatty liver disease“. Em conjunto formam uma impressão digital única.